Drug Profile


Alternative Names: BC-2059

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BetaCat Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Beta catenin inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Fibroma; Multiple myeloma

Most Recent Events

  • 13 Mar 2018 Beta Cat Pharmaceuticals plans a phase I trial for Fibroma (Recurrent, Inoperable/unresectable, Second-line therapy or greater) in March 2018 (NCT03459469)
  • 12 Apr 2017 BetaCat Pharmaceuticals has patents pending for transducin β-like protein 1 inhibitors in European Union, Eastern Europe, India, China, Japan, and Canada
  • 12 Apr 2017 BetaCat Pharmaceuticals has patent protection for transducin β-like protein 1 inhibitors in South Korea, Mexico, New Zealand, Singapore, South Africa, Eurasia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top